Innovimmune Biotherapeutics, Inc. logo

Innovimmune Biotherapeutics, Inc.

A leading R& D Biotech developing immunomodulatory drugs for the treatment of Autoimmune Diseases & Cancer. Innovoimmune Biotherapeutics, is developing proprietary oral small molecule immunomodulatory drugs targeting cytokine, chemokine and signal transduction pathways critical in the pathogenesis of Autoimmune Diseases and Cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.innovimmune.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
125 Maiden Lane,NY 10038
New York
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/innovimmune-biotherapeutics-inc-” connections=”true” suffix=””]

In July 2014, Innovimmune was awarded a $3 Mn, three-year (2014-2017) National Institute of Health (NIH) Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the preclinical development. Prior this Innovimmune recieved several other NIH grants totalling nearly $1Mn for the development of its pipeline.